✦ LIBER ✦

Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial

✍ Scribed by Delphine Rolland; Vincent Ribrag; Corinne Haioun; Herve Ghesquieres; Fabrice Jardin; Reda Bouabdallah; Patricia Franchi; Josette Briere; Eric De Kerviler; Catherine Chassagne-Clement; Mitch Raponi; Remi Houlgatte; Jean-Philippe Jais; Catherine Thieblemont

Book ID: 105993326
Publisher: Springer
Year: 2009
Tongue: English
Weight: 434 KB
Volume: 65
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-1185-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Patients with chemotherapy-refractory ma

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

✍ Owen A. O’Connor; Craig Moskowitz; Carol Portlock; Paul Hamlin; David Straus; Ot 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

Efficacy and safety of the combination o

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden : A multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)

✍ Franck Morschhauser; Nicolas Mounier; Catherine Sebban; Pauline Brice; Phillippe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB